Daemon Garso
Psychiatric/Mental Health · Ogden, UTNPI 1841769221
Payments from drug & device makers
Across 126 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$408
- Alkermes, Inc.$373
- Indivior Inc.$339
- Supernus Pharmaceuticals, Inc.$318
- Neurocrine Biosciences, Inc.$172
- Johnson & Johnson$156
- plus $581 from 10 others
What the payments were for
- Food & beverage$2,347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$218
How this compares
$2,347 in reported general payments places this provider in the 80th percentile of 393 psychiatric/mental health providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 14 | $39,360 |
| Invega SustennaPaliperidone Palmitate | 13 | $33,515 |
| VraylarCariprazine Hcl | 20 | $27,476 |
| VivitrolNaltrexone Microspheres | 12 | $18,888 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $4,690 |
| Methylphenidate ErMethylphenidate Hcl | 14 | $3,137 |
| Asenapine Maleate | 19 | $2,318 |
| Paliperidone ErPaliperidone | 13 | $1,579 |
| Propranolol Hcl ErPropranolol Hcl | 19 | $560 |
| Clozapine | 11 | $508 |
| Olanzapine | 20 | $466 |
| Quetiapine Fumarate | 28 | $457 |
| Prazosin Hcl | 21 | $430 |
| Memantine Hcl | 12 | $382 |
| Hydroxyzine Pamoate | 16 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Vivitrol | $373 | $58,24726 claims |
| Johnson & JohnsonInvega Sustenna | $156 | $33,51513 claims |
| AbbVieVraylar | $408 | $27,47620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 psychiatric/mental health providers in Utah.
Other psychiatric/mental health in Ogden
- Bret HafenLayton$381K
- Alberto SouzaSaint George$114K
- Anthony BrowningOrem$32K
- Debra HainRiverton$29K
- Kristin BarberSalt Lake City$28K
- Briana TerrySalt Lake City$14K
- Paige MarshallSaint George$13K
- Derick MoodySpringville$8K
- Sumer AndersonSandy$8K
- Colby JamesLayton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.